Invesco Ltd. Buys 22,301 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Invesco Ltd. lifted its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 14.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 181,714 shares of the company's stock after buying an additional 22,301 shares during the quarter. Invesco Ltd. owned about 0.59% of Fulgent Genetics worth $3,356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of FLGT. Barclays PLC grew its holdings in shares of Fulgent Genetics by 22.6% during the 3rd quarter. Barclays PLC now owns 174,855 shares of the company's stock worth $3,800,000 after acquiring an additional 32,250 shares during the period. Geode Capital Management LLC boosted its position in shares of Fulgent Genetics by 2.7% during the third quarter. Geode Capital Management LLC now owns 502,869 shares of the company's stock valued at $10,930,000 after purchasing an additional 13,320 shares in the last quarter. Franklin Resources Inc. purchased a new stake in Fulgent Genetics in the third quarter worth $215,000. JPMorgan Chase & Co. raised its holdings in Fulgent Genetics by 113.2% in the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company's stock worth $7,346,000 after purchasing an additional 179,477 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Fulgent Genetics by 45.5% during the fourth quarter. GAMMA Investing LLC now owns 2,133 shares of the company's stock valued at $39,000 after buying an additional 667 shares during the period. 48.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on FLGT shares. StockNews.com upgraded shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a research note on Wednesday, March 5th. Piper Sandler dropped their price target on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th.

Fulgent Genetics Stock Down 0.7 %

Shares of NASDAQ:FLGT traded down $0.13 on Thursday, hitting $17.22. 247,260 shares of the company traded hands, compared to its average volume of 262,150. The stock has a 50 day simple moving average of $17.37 and a 200-day simple moving average of $18.11. The company has a market cap of $531.51 million, a PE ratio of -3.12 and a beta of 1.36. Fulgent Genetics, Inc. has a 52 week low of $14.57 and a 52 week high of $25.11.

Insider Activity at Fulgent Genetics

In other Fulgent Genetics news, CFO Paul Kim bought 100,000 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were acquired at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the purchase, the chief financial officer now owns 348,282 shares in the company, valued at approximately $5,558,580.72. This trade represents a 40.28 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 31.76% of the stock is currently owned by insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.